Shanghai Pharmaceuticals (601607.SH): Hydroxychloroquine Sulfate Tablets Obtain Drug Registration Certificate in the Philippines

SH PHARMA (02607) to Distribute Interim Dividend of HK$1.3215 per 10 Shares on February 6, 2026

Shanghai Pharmaceuticals Holding Co. Ltd. held extraordinary general meeting

Shanghai Pharmaceuticals Terminates Cooperation Deal with Sinorg Biomedical

Shanghai Pharmaceuticals (601607.SH) Gains Approval for Minoxidil Tincture Production

SH PHARMA (02607) to Distribute Interim Dividend of RMB1.2 per 10 Shares

Shanghai Pharmaceuticals Holding Co. Ltd. proposes interim dividend of RMB 1.2 per 10 shares

Shanghai Pharmaceuticals (601607.SH): Cefuroxime Sodium for Injection and Aztreonam for Injection Pass Generic Drug Consistency Evaluation

Shanghai Pharmaceuticals (601607.SH) Receives FDA Approval for Ticagrelor Tablets

Shanghai Pharmaceuticals (601607.SH): Tofacitinib Citrate Sustained-Release Tablets Approved for Production

UBS Raises SH PHARMA (02607) Target Price to HK$15, Maintains "Buy" Rating

HK Stock Movement | SH PHARMA (02607) Drops Over 5% as Q3 Net Profit Falls 38.13% Due to Increased Asset Impairment Provisions

Shanghai Pharmaceuticals Plans to Distribute 1.2 Yuan Cash Dividend per 10 Shares

Shanghai Pharmaceuticals Holding Co. Ltd. proposes RMB445 million interim dividend for H1 2025

BRIEF-Shanghai Pharmaceuticals Q3 Net Profit Down 38.1% Y/Y

SIHL Subsidiary Signs One-Year Procurement Framework Agreement with Shanghai Pharmaceuticals Holding

Shanghai Pharmaceuticals (601607.SH): Pyridostigmine Bromide Sustained-Release Tablets Approved for Production

Shanghai Pharmaceuticals Holding Co., Ltd. (601607.SH) Subsidiary Becomes Holder of上市 License for Amasulpiride Oral Dispersible Tablet

Shanghai Pharmaceuticals Announces Equity Adjustment; No Change in Controlling Shareholder

Shanghai Pharmaceuticals - Shanghai Shangshi Increased Shareholding in Co From 25.303% to 38.487% Following Equity Adjustment